JP6250394B2 - 軽度の認知障害（ｍｃｉ）および関連障害の処置方法 - Google Patents

軽度の認知障害（ｍｃｉ）および関連障害の処置方法 Download PDF

Info

Publication number
JP6250394B2
JP6250394B2 JP2013525003A JP2013525003A JP6250394B2 JP 6250394 B2 JP6250394 B2 JP 6250394B2 JP 2013525003 A JP2013525003 A JP 2013525003A JP 2013525003 A JP2013525003 A JP 2013525003A JP 6250394 B2 JP6250394 B2 JP 6250394B2
Authority
JP
Japan
Prior art keywords
disease
administration
compound
app
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013525003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534256A5 (enExample
JP2013534256A (ja
Inventor
ヴァーゲス・ジョン
デイル・イー・ブレーデセン
Original Assignee
バック・インスティテュート・フォー・リサーチ・オン・エイジング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バック・インスティテュート・フォー・リサーチ・オン・エイジング filed Critical バック・インスティテュート・フォー・リサーチ・オン・エイジング
Publication of JP2013534256A publication Critical patent/JP2013534256A/ja
Publication of JP2013534256A5 publication Critical patent/JP2013534256A5/ja
Application granted granted Critical
Publication of JP6250394B2 publication Critical patent/JP6250394B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013525003A 2010-08-19 2011-08-19 軽度の認知障害（ｍｃｉ）および関連障害の処置方法 Active JP6250394B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40190710P 2010-08-19 2010-08-19
US61/401,907 2010-08-19
PCT/US2011/048472 WO2012024616A1 (en) 2010-08-19 2011-08-19 Methods of treating miild cognitive impairment (mci) and related discorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016160482A Division JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害（ｍｃｉ）および関連障害の処置方法

Publications (3)

Publication Number Publication Date
JP2013534256A JP2013534256A (ja) 2013-09-02
JP2013534256A5 JP2013534256A5 (enExample) 2014-10-09
JP6250394B2 true JP6250394B2 (ja) 2017-12-20

Family

ID=45605447

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013525003A Active JP6250394B2 (ja) 2010-08-19 2011-08-19 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
JP2016160482A Pending JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害（ｍｃｉ）および関連障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016160482A Pending JP2016193944A (ja) 2010-08-19 2016-08-18 軽度の認知障害（ｍｃｉ）および関連障害の処置方法

Country Status (10)

Country Link
US (1) US10449177B2 (enExample)
EP (1) EP2605655B1 (enExample)
JP (2) JP6250394B2 (enExample)
AU (1) AU2011291506B2 (enExample)
BR (1) BR112013003847A8 (enExample)
CA (1) CA2808630A1 (enExample)
DK (1) DK2605655T3 (enExample)
ES (1) ES2705027T3 (enExample)
MX (1) MX353096B (enExample)
WO (1) WO2012024616A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011291506B2 (en) 2010-08-19 2016-07-28 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
CA2881189A1 (en) 2012-08-07 2014-02-13 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
ES2769578T3 (es) 2013-02-12 2020-06-26 Buck Inst Res Aging Hidantoínas que modulan el procesamiento de APP mediado por BACE
WO2014152207A1 (en) 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
MX2016009753A (es) 2014-01-28 2017-07-07 Buck Inst For Res On Aging Metodos y composiciones para exterminar celulas senescentes y para tratar enfermedades y trastornos asociados con la senectud.
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US10471029B2 (en) 2014-03-21 2019-11-12 Alzheon, Inc. Methods for treating neurological disorders
CA2976258C (en) 2015-02-18 2024-02-20 Buck Institute For Research On Aging Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
US20180200259A1 (en) * 2015-05-18 2018-07-19 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOID ß
HUE062511T2 (hu) 2015-09-10 2023-11-28 Alzheon Inc Alzheimer-kór kezelése egy adott betegpopulációban
CA3007641C (en) 2015-12-09 2023-10-17 Brandeis University Dbh inhibitors for treating or preventing memory loss
US20180250249A1 (en) * 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population
AU2017264931B2 (en) 2016-05-12 2021-02-04 Buck Institute For Research On Aging Compounds to promote normal processing of APP
CN110382543B (zh) 2017-01-03 2023-12-26 生物蛋白有限公司 用于治疗衰老细胞的蛋白治疗剂
US11026963B2 (en) 2018-07-11 2021-06-08 Rubedo Life Sciences, Inc. Senolytic compositions and uses thereof
CN110232679A (zh) * 2019-05-24 2019-09-13 潘丹 一种阿尔茨海默症遗传生物标志物确定方法及系统
CN114555071A (zh) 2019-07-25 2022-05-27 学校法人东京理科大学 治疗、预防或改善精神/神经系统的疾病或症状的药剂

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS5936675A (ja) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
AU646877B2 (en) 1990-06-15 1994-03-10 Scios Nova Inc. Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
DK0971033T3 (da) 1991-01-21 2009-12-14 Elan Pharm Inc Test og model til Alzheimers sygdom
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5206264A (en) 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
EP0620849B1 (en) 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
ATE198622T1 (de) 1993-10-27 2001-01-15 Elan Pharm Inc Transgene tiere, die app allele mit der schwedischen mutation beherbergen
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
AU6383396A (en) 1995-06-07 1996-12-30 Athena Neurosciences, Inc. Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO2000003819A1 (en) 1998-07-17 2000-01-27 The Penn State Research Foundation Full form roll finishing technique
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
CN1502696A (zh) 1998-09-24 2004-06-09 �������Ŷ���Լ��������˾ 阿尔茨海默氏疾病分泌酶
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
JP4588221B2 (ja) 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
US20040092511A1 (en) 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20070059367A1 (en) 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US20020115727A1 (en) 2000-12-04 2002-08-22 Senanayake Chris H. Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
US20020107244A1 (en) 2001-02-02 2002-08-08 Howard Harry R. Combination treatment for depression
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
MXPA05004381A (es) 2002-10-25 2006-02-10 Collegium Pharmaceutical Inc Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos.
FR2846559B1 (fr) 2002-10-31 2007-06-15 Centre Nat Rech Scient Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
EP1724267B1 (en) 2004-02-26 2013-11-06 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivative
EP1755444B1 (en) 2004-04-21 2020-08-05 Mear Holding B.V. System for measuring pulsatile vascular resistance
EP1741430B1 (en) 2004-04-30 2009-07-15 National University Corporation Chiba University Remedy for psychoneurotic diseases
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
CN101132777A (zh) 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
JP2008525501A (ja) 2004-12-23 2008-07-17 ゼノポート，インコーポレイティド セリンアミノ酸誘導のプロポフォールのプロドラッグ、その使用及び結晶体
EP1874356A2 (en) 2005-04-15 2008-01-09 Board of Trustees of Michigan State University Aminergic pharmaceutical compositions and methods
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
CA2644458A1 (en) 2006-03-01 2007-09-07 Galderma Research & Development Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
ES2587014T3 (es) * 2006-11-24 2016-10-20 Ac Immune S.A. Derivados de N-(metil)-piridin-2-amina para el tratamiento de enfermedades asociadas a proteínas amiloides o de tipo amiloide
WO2008074896A1 (en) * 2006-12-21 2008-06-26 Prendergast Patrick T Compositions and methods for treatment of chronic neurological disorders
JP2010526080A (ja) 2007-05-03 2010-07-29 アルビサー，ジャック，エル． ホノキオール類縁体および癌治療へのそれらの使用
EP2219449A4 (en) 2007-11-16 2010-10-27 Univ Arizona State METHOD FOR THE TREATMENT OF EXPOSURE TO DAMAGING
CL2007003877A1 (es) 2007-12-28 2008-06-27 Univ De Concepcion Lab Androma Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina.
EP2273880B1 (en) 2008-04-28 2014-12-31 Zogenix, Inc. Novel formulations for treatment of migraine
WO2009155054A2 (en) 2008-05-29 2009-12-23 Albany Molecular Research, Inc. 5-ht3 receptor modulators, methods of making, and use thereof
US8604087B2 (en) 2008-09-25 2013-12-10 Bioland Ltd. Composition for treating or preventing amyloid-related diseases comprising 4-O-methylhonokiol
US9622977B2 (en) 2008-10-08 2017-04-18 Bioplus Life Sciences Pvt, Ltd. Sustained release drug delivery system
US20100099701A1 (en) 2008-10-20 2010-04-22 Auspex Pharmaceuticals, Inc. Isoquinolinone modulators of 5-ht3 receptors
CN101444508B (zh) 2008-12-29 2010-10-27 海南瑞基药物研究有限公司 一种注射用托烷司琼制剂及其制备方法
EP2432437A4 (en) 2009-05-21 2012-12-19 Bionex Pharmaceuticals Llc TWO- AND ONE-LAYER DOSAGE FORMS
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
US9790109B2 (en) * 2010-04-30 2017-10-17 General Electric Company Method for sanitizing an electrodeionization device
AU2011291506B2 (en) 2010-08-19 2016-07-28 Buck Institute For Age Research Methods of treating mild cognitive impairment (mci) and related disorders
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
WO2013123426A1 (en) 2012-02-18 2013-08-22 Buck Institute For Research On Aging Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer's conditions

Also Published As

Publication number Publication date
MX353096B (es) 2017-12-19
MX2013001917A (es) 2013-10-25
AU2011291506B2 (en) 2016-07-28
EP2605655B1 (en) 2018-10-24
US20120071468A1 (en) 2012-03-22
AU2011291506A1 (en) 2013-03-14
EP2605655A1 (en) 2013-06-26
US10449177B2 (en) 2019-10-22
JP2016193944A (ja) 2016-11-17
DK2605655T3 (en) 2019-02-04
BR112013003847A2 (pt) 2016-05-31
CA2808630A1 (en) 2012-02-23
BR112013003847A8 (pt) 2017-12-26
EP2605655A4 (en) 2014-01-08
JP2013534256A (ja) 2013-09-02
WO2012024616A1 (en) 2012-02-23
ES2705027T3 (es) 2019-03-21

Similar Documents

Publication Publication Date Title
JP6250394B2 (ja) 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
US10835546B2 (en) App specific BACE inhibitors (ASBIs) and uses thereof
US10766867B2 (en) Hydantoins that modulate BACE-mediated APP processing
EP2814491A1 (en) Formulations and methods for the treatment or prophylaxis of pre-mci and/or pre-alzheimer&#39;s conditions
CN109563089B (zh) 促进app正常加工的化合物
JP6830895B2 (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
US20220041553A1 (en) Apoe4-targeted theraputics that increase sirt1
US20220265605A1 (en) Methods of inducing autophagy using coumarin derivatives and related compounds
WO2025095099A1 (ja) 前頭側頭葉変性症治療剤及び治療用組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140819

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160106

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160906

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171122

R150 Certificate of patent or registration of utility model

Ref document number: 6250394

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250